Hansa Biopharma AB (publ) (HNSBF) Expected to Post Earnings on Wednesday

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) is expected to release its resultson Wednesday, November 11th. Analysts expect the company to post earnings of ($0.1411) per share and revenue of $41.30 million for the quarter.

Hansa Biopharma AB (publ) Stock Performance

Hansa Biopharma AB (publ) stock opened at $3.29 on Wednesday. The business has a 50-day simple moving average of $3.49 and a two-hundred day simple moving average of $3.12. Hansa Biopharma AB has a 52-week low of $2.90 and a 52-week high of $3.70.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ) is a Swedish biopharmaceutical company focused on developing enzyme-based immunomodulatory treatments for patients with rare immunological conditions. Its research centers on therapies that selectively modify or remove disease-causing antibodies, with applications in transplantation, autoimmune diseases and other areas involving the immune system.

The company’s primary product is Idefirix (imlifidase), an enzyme that cleaves immunoglobulin G (IgG) antibodies. Idefirix received conditional marketing authorization in the European Union in 2020 for the desensitization of highly sensitized adult kidney transplant patients who are otherwise unlikely to receive a compatible organ.